Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

Clinical Sarcoma Research

Lars M. Wagner¹ 

[1] Division of Pediatric Hematology/Oncology, Kentucky Clinic Suite, University of Kentucky, J-457, Lexington 40536, KY, USA

关键词: Rhabdomyosarcoma;    Ewing sarcoma;    Sarcoma;    Irinotecan;   

Others  :  1223052
DOI  :  10.1186/s13569-015-0035-x

 received in 2015-07-20, accepted in 2015-08-22,  发布年份 2015

【 摘 要 】

Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents.

【 授权许可】

   
2015 Wagner.

【 参考文献 】

• [1]Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC et al.. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol. 1999; 17:1815-1824.
• [2]Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK et al.. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol. 1995; 36:393-403.
• [3]Vassal G, Couanet D, Stockdale E, Geoffray A, Geoerger B, Orbach D et al.. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children’s Cancer Study Group. J Clin Oncol. 2007; 25:356-361.
• [4]Morland B, Platt K, Whelan JS. A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study. Pediatr Blood Cancer. 2014; 61:442-445.
• [5]Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006; 46:50-55.
• [6]Shitara T, Shimada A, Hanada R, Matsunaga T, Kawa K, Mugishima H et al.. Irinotecan for children with relapsed solid tumors. Pediatr Hematol Oncol. 2006; 23:103-110.
• [7]Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z et al.. Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2007; 25:4622-4627.
• [8]Cosetti M, Wexler LH, Calleja E, Trippett T, LaQuaglia M, Huvos AG et al.. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol. 2002; 24:101-105.
• [9]Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G et al.. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer. 2006; 106:703-707.
• [10]Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN et al.. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010; 28:4658-4663.
• [11]Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E et al.. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996; 56:3752-3757.
• [12]Wagner LM, Crews KR, Stewart CF, Rodriguez-Galindo C, McNall-Knapp RY et al.. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer. 2008; 50:201-207.
• [13]Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC et al.. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol. 2006; 24:563-570.
• [14]McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J et al.. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer. 2012; 58:372-379.
• [15]Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D et al.. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group. J Clin Oncol. 2007; 25:362-369.
• [16]O’Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006; 24:4534-4538.
• [17]Stewart CF, Panetta JC, O’Shaughnessy MA, Throm SL, Fraga CH, Owens T et al.. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007; 25:2594-2600.
• [18]Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP et al.. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol. 2009; 27:1290-1296.
• [19]Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA et al.. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol. 1999; 17:685-696.
• [20]Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD et al.. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children’s Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010; 54:538-545.
• [21]Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E et al.. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer. 2014; 61:833-839.
• [22]Brennan RC, Furman W, Mao S, Wu J, Turner DC, Stewart CF et al.. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol. 2014; 74:1191-1198.
• [23]Wagner LM. Oral irinotecan for treatment of pediatric solid tumors: ready for prime time? Pediatr Blood Cancer. 2010; 54:661-662.
• [24]Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J et al.. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004; 64:7491-7499.
• [25]Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL et al.. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol. 2009; 27:4599-4604.
• [26]Vassal G, Terrier-Lacombe MJ, Bissery MC, Vénuat AM, Gyergyay F, Bénard J et al.. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer. 1996; 74:537-545.
• [27]McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. Pediatr Blood Cancer. 2010; 54:909-915.
• [28]Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS et al.. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999; 5:3617-3631.
• [29]Hawkins DS, Anderson JR, Mascarenhas L, McGowage GB, Rodeberg DA, Wolden SL et al.. Vincristine, dactinomycin, cyclophosphamide (VAC versus VAC/V plus irinotecan for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue sarcoma Committee. J Clin Oncol. 2014; 32:suppl abstr 10004.
• [30]Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA et al.. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res. 2000; 6:4110-4118.
• [31]Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP et al.. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res. 2000; 6:4154-4157.
• [32]Pourquier P, Waltman JL, Urasaki Y, Loktionova NA, Pegg AE, Nitiss JL et al.. Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res. 2001; 61:53-58.
• [33]Kurucu N, Sari N, Ilhan IE. Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature. Pediatr Hematol Oncol. 2015; 32:50-59.
• [34]Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB et al.. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007; 48:132-139.
• [35]Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP et al.. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009; 53:1029-1034.
• [36]Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E et al.. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013; 60:1621-1625.
• [37]Mixon BA, Eckrich MJ, Lowas S, Engel ME. Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma. J Pediatr Hematol Oncol. 2013; 35:e163-e166.
• [38]Dharmarajan KV, Wexler LH, Wolden SL. Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study. Pediatr Blood Cancer. 2013; 60:242-247.
• [39]McGregor LM, Spunt SL, Furman WL, Stewart CF, Schaiquevich P, Krailo MD et al.. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children’s oncology group study. Cancer. 2009; 115:1765-1775.
• [40]Hartmann C, Weinel P, Schmid H, Grigull L, Sander A, Linderkamp C et al.. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. J Pediatr Hematol Oncol. 2011; 33:344-349.
• [41]Zak D, Styler MJ, Rosenbluth JZ, Brodsky I. Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma. Clin Adv Hematol Oncol. 2005; 3:297-299.
• [42]Crews KR, Stewart CF, Liu T, Rodriguez-Galindo C, Santana VM, Daw NC. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol. 2004; 26:764-767.
• [43]Yoon JH, Kwon MM, Park HJ, Park SY, Lim KY, Joo J et al.. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. BMC Cancer. 2014; 14:622. BioMed Central Full Text
• [44]Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M et al.. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma. Eur J Cancer. 2012; 48:253-262.
• [45]Mascarenhas L, Meyer WH, Lyden E, Rodeberg DA, Indelicato DJ, Linardic CM et al.. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine and cyclophosphamide for first relapse/disease progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2014; 32:suppl abstr 10003.
• [46]Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010; 16:183-194.
• [47]Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT et al.. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012; 30:256-262.
• [48]Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX et al.. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014; 61:452-456.
• [49]Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al.. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483:570-575.
• [50]Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ et al.. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014; 14:813. BioMed Central Full Text
• [51]Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H et al.. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2015; 21:819-832.
• [52]Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR et al.. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014; 9:829-841.
• [53]Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther. 2012; 11:174-182.
• [54]Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D et al.. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res. 2013; 15(73):776-784.
• [55]Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr Blood Cancer. 2013; 60:1447-1451.
• [56]Okada K, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y, Hara J. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors. Jpn J Clin Oncol. 2013; 43:1073-1079.
• [57]Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L et al.. Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res. 2010; 16:4809-4821.
• [58]Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E et al.. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014; 61:1792-1797.
• [59]Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT et al.. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013; 14:1216-1225.
• [60]Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D et al.. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J Clin Oncol. 2013; 31:4060-4066.
• [61]Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, Nielsen UB, Fitzgerald JB. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014; 74:7003-7013.
• [62]Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006; 66:3271-3277.
• [63]Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP et al.. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015; 21:1139-1150.